Demand for Medical Supplies Continues to Climb
An $8 Billion Market Affecting over 600 Million People…
Chronic obstructive pulmonary disease (COPD) is a lung ailment which restricts the passage of oxygen flow. Researchers estimate that 600 million people are affected by COPD worldwide. An enormous $8 billion is generated worldwide due to respiratory illness. As of today, COPD cannot be cured, but sufficient treatment can help slow COPD progression.
A Newly Discovered Stock Offering a Key Solution…
Ingen Technologies, Inc. (IGNT.PK) a medical device manufacturer specializing in the development of gravity-independent in-line oxygen flow meters built into a nasal cannula they dub “Oxyview”. Oxyview provides respiratory patients the ability to place an accurate oxygen flow measurement on a continual basis right at the source, eliminating guesswork by both patient and caretaker.
Why Buy Ingen Technologies Right Now?
1) COPD is a Large and Growing Market Showing No Signs of Slowdown!
There are 32 million U.S. patients with COPD, and 600 million patients worldwide. COPD cannot be cured, but treatment can be applied. $8 billion is a cost to the world market because of the disease.
2) Ingen Technologies Products are Patented!
Respiratory illnesses have substantially contributed to increased demand for health care products. IGNT has secured patents on products that it develops, markets, and distributes to the medical sector, assisting in the treatment of patients who are affected by respiratory diseases. Obtaining a patent on products which hold great potential will create barriers to entry, making it difficult for competitors to enter into the market. This allows the successful firm such as IGNT the ability to achieve long run profits.
3) Ingen Continues Building Shareholder Value!
Ingen was featured Side-by-side Mid and Large Cap Compaines like Baxter (BAX) at the Alpha-1 19th Annual National Education Conference. The company achieved a $2.6M note for its major note holders. IGNT is in the process of achieving global expansion and expectations are that products will reach the Chinese market by July 2010. Additional distribution channels continue to be put into place including government contracts! Ingens’ Oxyview stole the show at the Medtrade Spring conference in Las Vegas this May.
CONTACT: 888-288-5215 · Please read our Full Disclaimer pertaining to this article.
Request a Detailed Report on (IGNT)